Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 400
Filter
1.
BMJ Case Rep ; 16(11)2023 Nov 23.
Article in English | MEDLINE | ID: mdl-37996146

ABSTRACT

A woman in her 80s who presented with sudden abdominal pain and bloody stool associated with fever, dry cough and malaise, was found to be COVID-19 RT-PCR positive with fulminating necrotising amoebic colitis. She underwent right extended hemicolectomy with ileostomy and survived despite an unpredictable post-operative course, the need for aggressive intensive care and other major risk factors, and was discharged home after the twentieth day of her presentation.This case summarises the survival of a geriatric patient diagnosed with two lethal complications - amoebic colitis and COVID-19 respiratory infection with the aid of prompt surgical intervention and appropriate critical care.


Subject(s)
COVID-19 , Coinfection , Dysentery, Amebic , Female , Humans , Coinfection/diagnosis , Coinfection/complications , Colectomy , COVID-19/complications , Dysentery, Amebic/complications , Dysentery, Amebic/diagnosis , Ileostomy , Aged, 80 and over
2.
Clin J Gastroenterol ; 16(5): 689-692, 2023 Oct.
Article in English | MEDLINE | ID: mdl-37584867

ABSTRACT

Amoebiasis is a parasitic infection caused by the protozoan, Entamoeba histolytica. At times, amoebiasis is activated under immunosuppressive conditions such as chemotherapy. We report a case of fulminant amoebic colitis resulting from an asymptomatic Entamoeba histolytica infection, which was activated by chemotherapy for gastric cancer. The patient developed diarrhea and fever after three courses of chemotherapy for gastric cancer and was diagnosed with acute enteritis. A colonoscopy and biopsy were performed because of the bloody stool. Histopathological findings revealed amoebic invasion of the rectum. Therefore, the patient was diagnosed with amoebic colitis and was treated with metronidazole. Emergency surgery was performed because intestinal perforation was suspected after which his general condition improved and was discharged. Subsequently, gastric cancer surgery was performed and the patient was discharged without postoperative complications. Hence, amoebic colitis should be listed as a differential diagnosis, and a colonoscopic biopsy should be performed when colitis occurs during chemotherapy for cancer.


Subject(s)
Amebiasis , Dysentery, Amebic , Entamoeba histolytica , Stomach Neoplasms , Humans , Amebiasis/complications , Amebiasis/drug therapy , Dysentery, Amebic/drug therapy , Dysentery, Amebic/complications , Dysentery, Amebic/diagnosis , Metronidazole/therapeutic use , Stomach Neoplasms/drug therapy , Stomach Neoplasms/surgery , Stomach Neoplasms/complications
3.
Intern Med ; 62(16): 2341-2348, 2023 Aug 15.
Article in English | MEDLINE | ID: mdl-36575014

ABSTRACT

Pregnancy is a known risk factor for amebic enteritis, which develops into potentially fatal fulminant amebic enteritis in some cases. We describe a case of a 27-year-old non-immunosuppressed pregnant woman with fulminant amebic enteritis complicated with cytomegalovirus enteritis. She improved with intensive care and intravenous metronidazole and ganciclovir but eventually required subtotal colectomy for intestinal stenosis. It is difficult to diagnose amebic enteritis, especially in a non-endemic area. Amebic enteritis must be considered as a differential diagnosis for refractory diarrhea with bloody stools in women in the perinatal period, even those without immunosuppression.


Subject(s)
Dysentery, Amebic , Enteritis , Pregnancy , Humans , Female , Adult , Dysentery, Amebic/complications , Metronidazole , Ganciclovir , Risk Factors , Enteritis/complications , Enteritis/diagnosis
4.
J Infect Dev Ctries ; 16(4): 717-725, 2022 04 30.
Article in English | MEDLINE | ID: mdl-35544636

ABSTRACT

Intestinal amoebiasis is a parasitic infection caused by Entamoeba histolytica. It is commonly found in developing countries with poor hygiene. A rare, life-threatening complication of amoebiasis is fulminant necrotizing amoebic colitis (FulNAC). We report a 59-year-old male with acute lower right abdominal pain. Before coming to our institution, he was diagnosed with acute appendicitis. Extensive necrosis near the caecum involving the appendix and colon was observed intraoperatively. The patient underwent a right hemicolectomy, followed by an ileostomy and colostomy. Histopathologic examination confirmed the diagnosis of FulNAC. After the surgery, the patient was transferred to the high care unit and treated with metronidazole after histopathologic findings confirmed the etiology. The patient showed excellent response to the antibiotic prescribed, and the symptoms subsided. He was discharged from the hospital on day nine. Additionally, we reviewed fifty-one existing case reports on invasive intestinal amoebiasis worldwide, confirmed by histopathological examination following their preoperative diagnosis, surgery, pharmacology treatment, and outcomes. The learning point of this case is that intestinal amoebiasis should be considered a differential diagnosis for patients around fifty years old with bowel symptoms and travel history or living in tight quarters. Blood tests, radiological examinations, and serological evaluations are valuable diagnostic modalities. Metronidazole should be given as early as possible, and health promotion is recommended to prevent this disease in the population.


Subject(s)
Appendicitis , Dysentery, Amebic , Entamoeba histolytica , Acute Disease , Appendicitis/complications , Appendicitis/diagnosis , Appendicitis/surgery , Dysentery, Amebic/complications , Dysentery, Amebic/diagnosis , Dysentery, Amebic/drug therapy , Humans , Intestines , Male , Metronidazole/therapeutic use , Middle Aged
5.
Mod Rheumatol Case Rep ; 6(2): 270-272, 2022 06 24.
Article in English | MEDLINE | ID: mdl-35388431

ABSTRACT

Intestinal amoebiasis is caused by Entamoeba histolytica (E. histolytica) and is characterised by cecal lesions, multiple lesions, aphthae, and multiple exudative erosions. Intestinal Behçet's disease (BD) is a chronic inflammatory disorder that is characterised by multiple ulcers. Although the aetiologies of these two bowel diseases are unrelated, they are difficult to distinguish because they present similarly with inflammation and ulcers, especially if evidence of specific pathogens is not detected. Herein, we report a case of intestinal amoebiasis in a patient with BD. The patient underwent colonoscopy four times before intestinal amoebiasis was diagnosed. As intestinal BD was initially suspected, she received high-dose glucocorticoid therapy, which exacerbated her condition. Following exacerbation, she underwent colonoscopy, and E. histolytica was revealed. Deliberate care should be taken to distinguish between intestinal amoebiasis and intestinal BD, as the appropriate treatments for these diseases are entirely different.


Subject(s)
Behcet Syndrome , Dysentery, Amebic , Intestinal Diseases , Behcet Syndrome/complications , Behcet Syndrome/diagnosis , Colonoscopy/adverse effects , Dysentery, Amebic/complications , Dysentery, Amebic/diagnosis , Female , Humans , Intestinal Diseases/etiology , Ulcer
7.
Rev Peru Med Exp Salud Publica ; 38(3): 458-462, 2021.
Article in Spanish | MEDLINE | ID: mdl-34932748

ABSTRACT

We report the case of a 62-year-old male with cough and abdominal pain for two weeks, associated with pulmonary tomographic findings compatible with probable infection by SARS-CoV-2, and who received high doses of early corticotherapy as an outpatient. The patient showed clinical deterioration, was hospitalized and died in the immediate postoperative period due to acute surgical abdomen. The anatomopathological study showed parasitic structures with characteristics compatible with amebae, which was pointed to as the cause of a complicated acute fulminant colitis, with multiple perforations and acute peritonitis. Acute fulminant colitis due to intestinal amebiasis in the context of a patient with probable COVID-19 had not been previously reported in Peru. It is important to highlight the fulminant presentation with fatal outcome of this prevalent parasitic infection, in the context of corticosteroids use in a probable SARS-CoV-2 pulmonary infection.


Se reporta el caso de un varón de 62 años quien presentó tos y dolor abdominal por dos semanas, con hallazgos tomográficos pulmonares compatibles con probable infección por SARS-CoV-2, que recibió tempranamente corticoterapia a dosis altas y de manera ambulatoria. El paciente presentó evolución tórpida, fue hospitalizado y falleció en el posoperatorio inmediato por un cuadro de abdomen agudo quirúrgico. El estudio anatomopatológico mostró estructuras parasitarias con características compatibles con amebas, como causa de una colitis aguda fulminante complicada, con perforación múltiple y peritonitis aguda. La colitis aguda fulminante por amebiasis intestinal en el contexto de un paciente con probable COVID-19 no había sido reportada en el Perú. Resulta importante resaltar la presentación fulminante con desenlace fatal de esta infección parasitaria prevalente en nuestro medio, en el contexto del uso de corticoides ante una probable infección pulmonar por COVID-19.


Subject(s)
COVID-19 , Dysentery, Amebic , Peritonitis , Dysentery, Amebic/complications , Dysentery, Amebic/diagnosis , Humans , Male , Middle Aged , SARS-CoV-2
9.
Cesk Patol ; 56(2): 95-98, 2020.
Article in English | MEDLINE | ID: mdl-32493026

ABSTRACT

Amoebic colitis represents a common parasitic infection in developing countries. In western world, it is encountered only sporadically. The clinical presentation is usually non-specific, non-invasive laboratory tests are often false negative and endoscopic and histopathological appearance may mimic other illnesses, especially Crohns disease. The disease therefore harbours a huge risk of misdiagnosing and a proper diagnosis is usually challenging. We present a case of an amoebic colitis with Crohn-like features and negative parasitological testing in a 53-years-old woman, in which the final diagnosis was established on the basis of its histopathological examination.


Subject(s)
Crohn Disease , Dysentery, Amebic , Crohn Disease/complications , Crohn Disease/diagnosis , Crohn Disease/pathology , Diagnosis, Differential , Dysentery, Amebic/complications , Dysentery, Amebic/diagnosis , Dysentery, Amebic/pathology , Female , Humans , Middle Aged
10.
Medicine (Baltimore) ; 99(20): e20198, 2020 May.
Article in English | MEDLINE | ID: mdl-32443341

ABSTRACT

RATIONALE: Metronidazole is widely used for treating infection of anaerobic bacteria and protozoa. Metronidazole is generally well tolerated, although metronidazole-associated peripheral neuropathy (PN) and metronidazole-induced encephalopathy (MIE) have been reported as rare side effects. The most common sites of MIE involve the bilateral dentate nucleus of the cerebellum. Herein, we present a rare case of MIE with isolated corpus callosum involvement, with concomitant metronidazole-associated PN. PATIENT CONCERNS: A middle-aged man with ulcerative colitis was diagnosed with amoebic dysentery because of unhygienic eating. After receiving metronidazole (1.8 g/d, cumulative dose 61.2 g) for >1 month, he started to complain of continuous paresthesia of the limbs, and intermittent speech problems. Magnetic resonance imaging demonstrated an isolated lesion in the splenium of the corpus callosum. DIAGNOSIS: A diagnosis of reversible splenial lesion syndrome and PN was made. Given the patient's medical history, MIE and metronidazole-associated PN were considered. INTERVENTIONS: Metronidazole was stopped. Mecobalamine and vitamin B1 were used for adjuvant treatment. OUTCOMES: At 1.5 months after stopping metronidazole, his symptoms of numbness and hyperesthesia had not improved, although he felt less ill. The isolated lesion disappeared on follow-up magnetic resonance imaging. At 6 months later, the hyperesthesia symptoms remained, and he was unable to resume his previous work. CONCLUSIONS: Physicians should consider MIE in their differentials for reversible splenial lesion syndrome when encountering a patient with a history of metronidazole medication and symptoms of encephalopathy, especially with concomitant PN. Early identification of this metronidazole-related complication and early cessation of the drug are essential for treatment.


Subject(s)
Antiprotozoal Agents/adverse effects , Brain Diseases/chemically induced , Dysentery, Amebic/drug therapy , Metronidazole/adverse effects , Peripheral Nervous System Diseases/chemically induced , Adult , Aged , Brain Diseases/diagnosis , Corpus Callosum/diagnostic imaging , Corpus Callosum/drug effects , Corpus Callosum/pathology , Dysentery, Amebic/complications , Humans , Magnetic Resonance Imaging/methods , Male , Middle Aged , Thiamine/administration & dosage , Thiamine/therapeutic use , Treatment Outcome , Vitamin B 12/administration & dosage , Vitamin B 12/analogs & derivatives , Vitamin B 12/therapeutic use , Vitamin B Complex/administration & dosage , Vitamin B Complex/therapeutic use , Withholding Treatment
11.
J Infect Dev Ctries ; 14(3): 321-322, 2020 03 31.
Article in English | MEDLINE | ID: mdl-32235095

ABSTRACT

Endolimax nana is a commensal protozoan of the colon. We report a case of chronic urticaria associated with E. nana in a 34-year-old Italian woman. The patient suffered from abdominal pain, diarrhoea and weight loss. The disease appeared after a trip to Vietnam. Laboratory examinations showed mild blood eosinophilia. Three coproparasitological examinations were positive for cysts of E. nana. The patient was successfully treated with two courses of metronidazole (2 g/day for 10 days each). No antihistamines were used. Three coproparasitological examinations, carried out at the end of the therapy, were negative. Follow up (six months) was negative. E. nana can be responsible for very rare cases of abdominal pain, diarrhoea, polyarthritis and urticaria.


Subject(s)
Dysentery, Amebic/diagnosis , Endolimax/isolation & purification , Travel , Abdominal Pain/etiology , Adult , Antiprotozoal Agents/administration & dosage , Antiprotozoal Agents/therapeutic use , Dysentery, Amebic/complications , Dysentery, Amebic/drug therapy , Feces/parasitology , Female , Humans , Italy , Metronidazole/administration & dosage , Metronidazole/therapeutic use , Urticaria/etiology
12.
Gac Med Mex ; 155(Suppl 1): S32-S37, 2019.
Article in Spanish | MEDLINE | ID: mdl-31182876

ABSTRACT

INTRODUCTION: In Mexico, seroprevalence of Entamoeba histolytica is 8.4%. The intestinal amebiasis in patients with acute leukemia of novo, after the start of chemotherapy (CT) in the Hematology Service of the CMN 20 de Noviembre is 12%, even if patients show a negative baseline coprological test. OBJECTIVE: To find out if the administration of tinidazole, in patients with acute leukemia and negative coprological test, at the beginning of the CT, decreases the incidence of amoebic colitis during the induction to remission. METHOD: Prospective and not comparative study. Patients with de novo diagnosis of acute leukemia who initiate induction and initial coprological CT. Tinidazole was indicated, 2 g/day for 5 days in the first week of CT started. They were monitored until the induction was concluded and hematopoietic recovery started. RESULTS: 38 patients, 15 women and 23 men with a mean age of 44 years (16-72), with acute lymphoblastic leukemia 19, myeloblastic 16 and promyelocytic 3. Cases without and with intestinal amebiasis were 35 and 3, respectively. Patients with amebiasis only received tinidazole for 3 days and it was given 2 days after the CT started. CONCLUSION: Tinidazole, in patients with acute de novo leukemia who initiate induction CT, is effective in the prevention of intestinal amebiasis, during the induction stage, if administered at 2 g/day, for five days, starting on day 1 of the CT.


INTRODUCCIÓN: En México la seroprevalencia de la Entamoeba histolytica es del 8.4%. La amebiasis intestinal en pacientes con leucemia aguda de novo posterior al inicio de quimioterapia (QT), en el Servicio de Hematología del CMN 20 de Noviembre, es del 12%, aún si muestran test coprológico negativo basal. OBJETIVO: Averiguar si la administración de tinidazol, en pacientes con leucemia aguda y coprológico negativo, al principio de la QT, disminuye la incidencia de colitis amebiana durante la inducción a la remisión. MÉTODO: Prospectivo y no comparativo. Enfermos con diagnóstico de leucemia aguda de novo que inician QT de inducción y coprológico inicial. Se indicó tinidazol, 2 g/día durante 5 días en la primera semana de comenzada QT. Se vigilaron hasta que la inducción concluyó y se inició la recuperación hematopoyética. RESULTADOS: 38 pacientes, 15 mujeres y 23 hombres con edad media de 44 años (16-72). Con leucemia aguda linfoblástica 19, con mieloblástica 16 y con promielocítica 3. Casos sin y con amebiasis intestinal, 35 y 3, respectivamente. Los pacientes con amebiasis solo recibieron tinidazol durante 3 días y se dio después de 2 días de empezada la QT. CONCLUSIÓN: El tinidazol, en pacientes con leucemia aguda de novo que inician QT de inducción, es efectivo en la prevención de la amebiasis intestinal, durante la etapa de inducción, si se administra a 2 g/día, durante cinco días, a partir del día 1 de la QT.


Subject(s)
Colitis/prevention & control , Colitis/parasitology , Dysentery, Amebic/prevention & control , Tinidazole/therapeutic use , Adolescent , Adult , Aged , Antineoplastic Agents/therapeutic use , Colitis/complications , Dysentery, Amebic/complications , Female , Humans , Leukemia, Myeloid, Acute/complications , Leukemia, Myeloid, Acute/drug therapy , Male , Middle Aged , Prospective Studies , Treatment Outcome , Young Adult
13.
Ann Ital Chir ; 82019 Apr 12.
Article in English | MEDLINE | ID: mdl-31148546

ABSTRACT

Splenic abscess is a rare condition, which is often asymptomatic in the absence of comorbidity and is associated with high mortality rates. Given the importance of the differential diagnosis of patients who present to the emergency department with fever or septic shock, we report the case of a patient with amoebic splenic abscess who presented to our clinic with widespread skin rash and signs of septic shock following amoebic dysentery caused by Entamoeba histolytica, which is rarely reported in the literature. KEY WORDS: Amoebic Spleen Abscess, Amoebic Abscess, Entamoeba Histolytica, Splenic Abscess.


Subject(s)
Abscess/etiology , Dysentery, Amebic/complications , Entamoeba histolytica/isolation & purification , Splenic Diseases/etiology , Abscess/parasitology , Abscess/surgery , Adult , Amebicides/therapeutic use , Anti-Bacterial Agents/therapeutic use , Bacteremia/complications , Bacteremia/drug therapy , Combined Modality Therapy , Cross Infection/complications , Cross Infection/drug therapy , Humans , Male , Metronidazole/therapeutic use , Purpura/etiology , Shock, Septic/etiology , Splenectomy , Splenic Diseases/parasitology , Splenic Diseases/surgery
16.
Paediatr Int Child Health ; 39(1): 73-75, 2019 02.
Article in English | MEDLINE | ID: mdl-29737935

ABSTRACT

Entamoeba histolytica is a protozoan parasite that affects a large proportion of the world's population and causes amoebic dysentery and extra-intestinal disease. Many individuals remain asymptomatic during colonisation; in 10% of individuals, the parasite breaks through the mucosal barrier and leads to invasive disease. An eight-month-old girl who was evaluated for hypo-albuminaemia and was diagnosed with amoebic colitis is reported. To the best of our knowledge, this is the first report of hypo-albuminaemia owing to amoebic colitis in any age group.


Subject(s)
Dysentery, Amebic/diagnosis , Dysentery, Amebic/pathology , Entamoeba histolytica/isolation & purification , Entamoebiasis/diagnosis , Entamoebiasis/pathology , Hypoalbuminemia/etiology , Hypoalbuminemia/pathology , Breast Feeding , Dysentery, Amebic/complications , Entamoebiasis/complications , Female , Humans , Infant
17.
Gac. méd. Méx ; 155(supl.1): 32-37, dic. 2019. tab
Article in Spanish | LILACS | ID: biblio-1286562

ABSTRACT

Resumen Introducción: En México la seroprevalencia de la Entamoeba histolytica es del 8.4%. La amebiasis intestinal en pacientes con leucemia aguda de novo posterior al inicio de quimioterapia (QT), en el Servicio de Hematología del CMN 20 de Noviembre, es del 12%, aún si muestran test coprológico negativo basal. Objetivo: Averiguar si la administración de tinidazol, en pacientes con leucemia aguda y coprológico negativo, al principio de la QT, disminuye la incidencia de colitis amebiana durante la inducción a la remisión. Método: Prospectivo y no comparativo. Enfermos con diagnóstico de leucemia aguda de novo que inician QT de inducción y coprológico inicial. Se indicó tinidazol, 2 g/día durante 5 días en la primera semana de comenzada QT. Se vigilaron hasta que la inducción concluyó y se inició la recuperación hematopoyética. Resultados: 38 pacientes, 15 mujeres y 23 hombres con edad media de 44 años (16-72). Con leucemia aguda linfoblástica 19, con mieloblástica 16 y con promielocítica 3. Casos sin y con amebiasis intestinal, 35 y 3, respectivamente. Los pacientes con amebiasis solo recibieron tinidazol durante 3 días y se dio después de 2 días de empezada la QT. Conclusión: El tinidazol, en pacientes con leucemia aguda de novo que inician QT de inducción, es efectivo en la prevención de la amebiasis intestinal, durante la etapa de inducción, si se administra a 2 g/día, durante cinco días, a partir del día 1 de la QT.


Abstract Introduction: In Mexico, seroprevalence of Entamoeba histolytica is 8.4%. The intestinal amebiasis in patients with acute leukemia of novo, after the start of chemotherapy (CT) in the Hematology Service of the CMN 20 de Noviembre is 12%, even if patients show a negative baseline coprological test. Objective: To find out if the administration of tinidazole, in patients with acute leukemia and negative coprological test, at the beginning of the CT, decreases the incidence of amoebic colitis during the induction to remission. Method: Prospective and not comparative study. Patients with de novo diagnosis of acute leukemia who initiate induction and initial coprological CT. Tinidazole was indicated, 2 g/day for 5 days in the first week of CT started. They were monitored until the induction was concluded and hematopoietic recovery started. Results: 38 patients, 15 women and 23 men with a mean age of 44 years (16-72), with acute lymphoblastic leukemia 19, myeloblastic 16 and promyelocytic 3. Cases without and with intestinal amebiasis were 35 and 3, respectively. Patients with amebiasis only received tinidazole for 3 days and it was given 2 days after the CT started. Conclusion: Tinidazole, in patients with acute de novo leukemia who initiate induction CT, is effective in the prevention of intestinal amebiasis, during the induction stage, if administered at 2 g/day, for five days, starting on day 1 of the CT.


Subject(s)
Humans , Male , Female , Adolescent , Adult , Middle Aged , Aged , Young Adult , Tinidazole/therapeutic use , Colitis/parasitology , Colitis/prevention & control , Dysentery, Amebic/prevention & control , Leukemia, Myeloid, Acute/complications , Leukemia, Myeloid, Acute/drug therapy , Prospective Studies , Treatment Outcome , Colitis/complications , Dysentery, Amebic/complications , Antineoplastic Agents/therapeutic use
19.
Intern Med ; 57(13): 1855-1860, 2018 Jul 01.
Article in English | MEDLINE | ID: mdl-29491283

ABSTRACT

We herein report a case of simultaneous amebic colitis and cytomegalovirus (CMV) enteritis in an HIV-infected patient. The patient was a 40-year-old man who developed bloody stool and diarrhea. We diagnosed him with severe amebic colitis associated with HIV infection and administered metronidazole. While his symptoms began to improve, the patient then developed CMV enteritis. We administered ganciclovir, and his symptoms improved. However, despite control of the infection, stenosis of the descending colon caused intestinal obstruction, and colostomy was performed. This case shows the importance of considering the possibility of simultaneous infection when gastrointestinal symptoms appear in people infected with HIV.


Subject(s)
Antiviral Agents/therapeutic use , Colitis/surgery , Cytomegalovirus Infections/drug therapy , Dysentery, Amebic/drug therapy , Enteritis/surgery , Ganciclovir/therapeutic use , HIV Infections/complications , Adult , Colitis/complications , Colitis/diagnosis , Colitis/drug therapy , Colostomy , Cytomegalovirus Infections/complications , Dysentery, Amebic/complications , Enteritis/complications , Enteritis/drug therapy , Humans , Male , Treatment Outcome
SELECTION OF CITATIONS
SEARCH DETAIL
...